Highest-materiality recent filing
Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share
Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
Dyadic receives Nasdaq deficiency notice for continued listing rule non-compliance
Received notice on March 27, 2026 for non-compliance with Nasdaq Listing Rule 5550(b) requiring $2.5M equity, $35M market value, or $500K net income.
Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M
Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.
ATM facility allows Dyadic to sell up to $4,237,818 of common stock at prevailing market prices through Craig-Hallum as sales agent.
Received Nasdaq deficiency notice on Dec 19, 2025; bid price below $1 for 30 consecutive business days.
Dyadic extends convertible note maturity to Dec 2027, conversion price set at $1.05
Maturity of Senior Secured Convertible Notes extended from March 8, 2027 to December 31, 2027.
Dyadic International Reports Q3 2025 Financial Results and Strategic Progress
Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.
Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes
Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.
Dyadic amends security agreement; CEO's trust added as secured party for $1M note purchase
CEO Mark Emalfarb purchased and was assigned a $1,000,000 Senior Secured Convertible Promissory Note due March 8, 2027.
Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering
Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).
Dyadic International prices 6.05M-share public offering at $0.95, net ~$5.3M
Offering of 6,052,000 shares at $0.95 per share; expected net proceeds approximately $5.3 million.
Dyadic receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Nasdaq notified Dyadic that its common stock bid price closed below $1 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
Dyadic posts strategic presentation; no specific financial or operational updates
Presentation posted July 23, 2025 highlights transition from research to commercial focus.
Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant
Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.
Dyadic receives Nasdaq deficiency notice for MVLS below $35M threshold
Nasdaq staff notified Dyadic on June 23 that MVLS was below $35M for 30 consecutive business days.
Dyadic shareholders re-elect Emalfarb, ratify Crowe, and adopt annual say-on-pay at 2025 meeting
Mark A. Emalfarb re-elected Class III director with 15,946,385 votes for, 421,896 withheld; 7,892,709 broker non-votes.
Hazelton promoted to President, continues as COO; base salary raised 10% to $320,000; 25,000-share option grant with 4-year vesting.
On May 29, 2025, the board of directors (the "Board") of Dyadic International, Inc. (the "Company") appointed Joseph Hazelton as President of the Company.
Max materiality 0.90 · Median 0.65 · Most common event other_material